316 related articles for article (PubMed ID: 27923629)
1. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
4. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
5. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer.
Masago K; Fujita S; Hatachi Y; Fukuhara A; Sakuma K; Ichikawa M; Kim YH; Mio T; Mishima M
Cancer Sci; 2008 Nov; 99(11):2295-301. PubMed ID: 18811692
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.
Nishio M; Goto K; Chikamori K; Hida T; Katakami N; Maemondo M; Ohishi N; Tamura T
Clin Lung Cancer; 2016 Jan; 17(1):24-9.e1. PubMed ID: 26336854
[TBL] [Abstract][Full Text] [Related]
9. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
[TBL] [Abstract][Full Text] [Related]
10. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
11. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
12. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
[TBL] [Abstract][Full Text] [Related]
13. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
14. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
[TBL] [Abstract][Full Text] [Related]
15. Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand.
Saiyaros K; Kritpetcharat P; Pairojkul C; Sithithaworn J
Asian Pac J Cancer Prev; 2019 May; 20(5):1339-1343. PubMed ID: 31127887
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
Rusch V; Baselga J; Cordon-Cardo C; Orazem J; Zaman M; Hoda S; McIntosh J; Kurie J; Dmitrovsky E
Cancer Res; 1993 May; 53(10 Suppl):2379-85. PubMed ID: 7683573
[TBL] [Abstract][Full Text] [Related]
17. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Molina-Vila MA; Bertran-Alamillo J; Reguart N; Taron M; Castellà E; Llatjós M; Costa C; Mayo C; Pradas A; Queralt C; Botia M; Pérez-Cano M; Carrasco E; Tomàs M; Mate JL; Moran T; Rosell R
J Thorac Oncol; 2008 Nov; 3(11):1224-35. PubMed ID: 18978556
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
19. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
[TBL] [Abstract][Full Text] [Related]
20. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]